We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Multiple Clostridium Difficile Strains Cause Severe Patient Outcomes

By LabMedica International staff writers
Posted on 08 Sep 2015
Clostridium difficile is the most common cause of hospital acquired infections in the USA and the incidence of C. More...
difficile infection (CDI) has increased dramatically since 2001, coinciding with the emergence of the epidemic ribotype 027 (R027).

The high mortality rate associated with R027 led to it being described as a hypervirulent strain and since that characterization, additional ribotypes of C. difficile have been described as hypervirulent using similar criteria, but the impact of C. difficile ribotype on disease outcomes remains unclear, especially in endemic rather than epidemic settings.

Scientists at the University of Houston College of Pharmacy (Houston, TX, USA) and their colleagues collected and cultured stool samples that tested positive for C. difficile toxin from patients who presented to any of seven different local hospitals from 2011 to 2013. The study included 715 patients aged 61 ± 18 years with females making up 63% of the study population.

Enzyme-linked immunoassay or a polymerase-chain reaction (PCR) detection of the tcdB gene in unformed stool was the diagnostic methodology used at all study sites during the study period. C. difficile toxin-positive stool samples were plated onto cefoxitin-cycloserine-fructose agar (CCFA) plates and incubated under strict anaerobic conditions for 48 to 72 hours. The growth of toxigenic C. difficile was confirmed using multiplex PCR to determine the presence of tcdA, tcdB, and binary toxin genes and fluorescent ribotyping was performed.

In this large multicenter study, C. difficile R027 was the most common ribotype and was associated with severe CDI presentation and severe CDI outcomes. Although R027 was independently associated with severe disease, R027 was not independently associated with severe outcomes. No single strain was more virulent than the others. The ribotype 014-020 was associated with significantly lower incidence of severe CDI and severe CDI outcomes compared with other ribotypes.

Samuel L. Aitken, PharmD, the lead author of the study, said, “Clinical severity markers of CDI, such as white blood cell count and albumin level, a protein in blood, are more important predictors of severe outcomes than any specific strain, especially in hospitals with no single predominant strain. Strain typing remains a valuable source of information for tracking emergence of different strains and may potentially influence treatment decisions, but clinical severity markers appear to be more important predictors for the determining the severity of CDI patient outcomes.” The study was published on August 20, 2015, in the journal Infection Control & Hospital Epidemiology.

Related Links:
University of Houston College of Pharmacy



New
Gold Member
Blood Gas Analyzer
Stat Profile pHOx
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Gold Member
Automated Cell Culture Chemistry Analyzer
BioProfile FLEX2 Basic
New
Rapid Test Reader
DIA5000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: CellLENS enables the potential precision therapy strategies against specific immune cell populations in the tissue environment (Photo courtesy of MIT)

New AI System Uncovers Hidden Cell Subtypes to Advance Cancer Immunotherapy

To produce effective targeted therapies for cancer, scientists need to isolate the genetic and phenotypic characteristics of cancer cells, both within and across different tumors. These differences significantly... Read more

Pathology

view channel
Image: Micrograph showing the distribution of misfolded proteins in myeloma cells (Photo courtesy of Helmholtz Munich)

Novel Method Tracks Cancer Treatment in Cells Without Dyes or Labels

Multiple myeloma is a blood cancer that affects plasma cells in the bone marrow, leading to abnormal protein production, weakened immunity, and organ damage. Traditional methods for evaluating myeloma... Read more

Technology

view channel
Image: Researchers Dr. Lee Eun Sook and Dr. Lee Jinhyung examine the imprinting equipment used for nanodisk synthesis (Photo courtesy of KRISS)

Multifunctional Nanomaterial Simultaneously Performs Cancer Diagnosis, Treatment, and Immune Activation

Cancer treatments, including surgery, radiation therapy, and chemotherapy, have significant limitations. These treatments not only target cancerous areas but also damage healthy tissues, causing side effects... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.